Microbiotica
Series C
Microbiotica develops defined live bacterial therapeutics for immuno-oncology and inflammatory bowel disease, using a clinic-led discovery platform to identify bacteria associated with patient outcomes and select relevant patient populations. Its methods include gut bacterial culturing, microbiome analysis, reference genome databases, bioinformatics, and microbiome–host biology research.
About Microbiotica
FundFinder classes it as Health & Bio.
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Microbiotica? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series C · Oct 2026
Investors
Cambridge Innovation Capital
Cambridge Innovation Capital- Cambridge Innovation Capital — Cambridge-based fund managing over £500M, one of the most active Series A deeptech and life sciences investors in the Cambridge ecosystem (Pragmatic, Riverlane, Gyroscope); launched a £100M Opportunity Fund in 2025 backe